The role of paracetamol in chronic pain: An evidence-based approach

American Journal of Therapeutics

Volumn 12, Issue 1, 2005, Pages 80-91

  Nikles, C Jane ^a   Yelland, Michael ^a   Del Mar, Chris ^b   Wilkinson, David ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b BOND UNIVERSITY   (Australia)

Author keywords

Acetaminophen; Chronic pain; n of 1 trial; Osteoarthritis; Paracetamol

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CODEINE; DEXTROPROPOXYPHENE; DICLOFENAC; DIHYDROCODEINE; IBUPROFEN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PIROXICAM; PLACEBO; ROFECOXIB; TIAPROFENIC ACID; TRAMADOL;

CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LOW BACK PAIN; MAJOR CLINICAL STUDY; NEUROPATHIC PAIN; OSTEOARTHRITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW;

ACETAMINOPHEN; AGED; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; OSTEOARTHRITIS; PAIN; PAIN MEASUREMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS;

EID: 17144392222     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200501000-00011     Document Type: Review

References (92)

1. IASP Task Force of Taxonomy. In: Merskey H, Bogduk N, eds. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd ed. Seattle: IASP Press, 1994. pp. 209-214.
2. Mashford ML. Therapeutic Guidelines: Analgesic. North Melbourne: Therapeutic Guidelines, 2002.
3. Goucke CR. The management of persistent pain. Med J Aust. 2003;178:444-447.
4. Blyth FM, March LM, Brnabic AJ, et al. Chronic pain in Australia: a prevalence study. Pain. 2001;89:127-134.
5. Blyth FM, March LM, Cousins MJ. Chronic pain-related disability and use of analgesia and health services in a Sydney community. Med J Aust. 2003;179:84-87.
6. Lipman AG. Treatment of chronic pain in osteoarthritis: do opioids have a clinical role? Curr Rheumatol Rep. 2001; 3:513-519.
7. Kerr S, Fairbrother G, Crawford M, et al. Patient characteristics and quality of life among a sample of Australian chronic pain clinic attendees. Intern Med J. 2004;34:403-409.
8. Nikles CJ, Glasziou PP, Del Mar CB, et al. Preliminary experiences with a single-patient trials service in general practice. Med J Aust. 2000;173:100-103.
9. Day RO, Graham GG, Whelton A. The position of paracetamol in the world of analgesics. Am J Ther. 2000;7: 51-54.
10. Bannwarth B, Pehourcq F. [Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues]. Drugs. 2003;63:5-13.
11. Moore A, Collins S, Carroll D, et al. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain. 1997;70:193-201.
12. Moore A, Collins S, Carroll D, et al. Single dose paracetamol (acetaminophen), with and without codeine, for postoperative pain. The Cochrane Library, 1st ed. Oxford: Update Software, 2003.
13. Jordan KM, Anden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
14. American College of Rheumatology Subcommittee on Osteoarthritis. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43:1905-1915.
15. Koes BW, Sanders RJ, Tuut MK. [The Dutch Institute for Health Care Improvement (CBO) guideline for the diagnosis and treatment of aspecific acute and chronic low back complaints]. Ned Tijdschr Geneeskd. 2004;148: 310-314.
16. Abramson SB. Et tu, acetaminophen? Arthritis Rheum. 2002;46:2831-2835.
17. Hochberg MC. What a difference a year makes: reflections on the ACR recommendations for the medical management of osteoarthritis. Curr Rheumatol Rep. 2001;3:473-478.
18. Amadio P, Cummings DM. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res. 1983;34:59-66.
19. Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med. 2003;163:169-178.
20. Pincus T, Fort JF, Mangal B, et al. Patient preference for placebo, acetaminophen (paracetamol), or Celebrex effectiveness study (PACES-1): a double-blinded, randomized, cross-over clinical trial in patients with osteoarthritis of the hip or knee. Ann Rheum Dis. 2003; 62(suppl 1):73.
21. Zoppi M, Peretti G, Boccard E. Placebo-controlled study of the analgesic efficacy of an effervescent formulation of 500 mg paracetamol in arthritis of the knee or hip. Eur J Pain. 1995;16:42-48.
22. Pincus T, Koch G, Lei H, et al. Patient preference for Placebo, Acetaminophen or Celecoxib Efficacy Studies (PACES): two randomized placebo-controlled cross-over clinical trials in patients with osteoarthritis of the knee or hip. Ann Rheum Dis. 2004;63:931-939.
23. Miceli-Richard C, Le BM, Schmidely N, et al. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis. 2004;63:923-930.
24. Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum. 2001,44:1587-1598.
25. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA. 2002;287:64-71.
26. March L, Irwig L, Schwarz J, et al. n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ. 1994;309:1041-1045.
27. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36:1196-1206.
28. Shen H, Sprott H, Aeschlimann A, et al. Primary analgesic action of acetaminophen and rofecoxib in osteoarthritis. Ann Rheum Dis. 2003;62(suppl 1):258.
29. Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis. 2004;63:1028-1034.
30. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325: 87-91.
31. Neame R, Zhang W, Doherty M. A historic issue of the Annals: three papers examine paracetamol in osteoarthritis. Ann Rheum Dis. 2004;63:897-900.
32. Towheed TE, Judd MJ, Hochberg MC, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2003; CD004257.
33. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004;63:901-907.
34. Matheson AJ, Perry CM. Glucosamine: a review of its use in the management of osteoarthritis. Drugs Aging. 2003; 20:1041-1060.
35. Zerkak D, Dougados M. The use of glucosamine therapy in osteoarthritis. Curr Rheumatol Rep. 2004;6:41-45.
36. Davenport G. Rheumatology and musculoskeletal medicine. Br J Gen Pract. 2004;54:457-464.
37. van Tulder MW, Scholten RJ, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine. 2000;25:2501-2513.
38. van Tulder MW, Scholten RJ, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2000; CD000396.
39. World Health Organization. WHO's Pain Ladder (available at www.who.int/cancer/palliative/painladder). Accessed May 28, 2004. Geneva: WHO, 2004.
40. Nikolaus T, Zeyfang A. Pharmacological treatments for persistent non-malignant pain in older persons. Drugs Aging. 2004;21:19-41.
41. Ehrlich GE. Low back pain. Bull World Health Org. 2003; 81:671-676.
42. Kjaersgaard-Andersen P, Nafei A, Skov O, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Pain. 1990;43:309-318.
43. Schnitzer TJ. Non-NSAID pharmacologic treatment options for the management of chronic pain. Am J Med. 1998;105:45S-52S.
44. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. 1998;25:1358-1363.
45. Muller FO, Odendaal CL, Muller FR, et al. Comparison of the efficacy and tolerability of a paracetamol/codeine fixed-dose combination with tramadol in patients with refractory chronic back pain. Arzneimittelforschung. 1998; 48:675-679.
46. Adler L, McDonald C, O'Brien C, et al. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol. 2002;29: 2196-2199.
47. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28:59-71.
48. Emkey R, Rosenthal N, Wu SC, et al. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol. 2004;31:150-156.
49. Ruoff GE, Rosenthal N, Jordan D, et al. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther. 2003;25:1123-1141.
50. Paracetamol + tramadol: new preparation. No advance. Prescrire Int. 2003;12:211-213.
51. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26:862-869.
52. Lloyd RS, Costello F, Eves MJ, et al. The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/ paracetamol tablets in patients with severe osteoarthritis of the hips. Curr Med Res Opin. 1992;13:37-48.
53. AGS clinical practice guidelines: the management of chronic pain in older persons. Geriatrics. 1998;53(suppl 3): S6-S7.
54. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541-1546.
55. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum. 1995;38:1535-1540.
56. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ. 1998;317:526-530.
57. Jenkins C. Recommending analgesics for people with asthma. Am J Ther. 2000;7:55-61.
58. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328:434.
59. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther. 2000;7:63-74.
60. Whelton A. Renal effects of over-the-counter analgesics. J Clin Pharmacol. 1995;35:454-463.
61. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther. 2000;7:99-114.
62. Bannwarth B. Gastrointestinal safety of paracetamol: is there any cause for concern? Expert Opin Drug Saf. 2004;3: 269-272.
63. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3:98-101.
64. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563-7568.
65. Signorello LB, McLaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9:199-205.
66. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000;7:115-121.
67. Graham GG, Graham RI, Day RO. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). Curr Pharm Des. 2002;8:1063-1075.
68. Moore N, van Ganse E, Le Parc JM, et al. The PAIN study: Paracetamol, aspirin and ibuprofen new tolerability study. A large-scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest. 1999;18:89-98.
69. Doyle G, Furey S, Berlin R, et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther. 1999;13:897-906.
70. Singh G, Ramey DR, Balise R, et al. Serious gastrointestinal complications of over-the-counter NSAIDs. Digestion. 1998;5:4.
71. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective 1997. J Rheumatol. 1998;25:8-16.
72. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: A view from the ARAMIS database. Am J Ther. 2000;7:115-121.
73. Tarone RE, Blot WJ, McLaughlin JK. Nonselective non-aspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther. 2004;11:17-25.
74. Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85:169-182.
75. National Prescribing Service. Medicines and older people: an accident waiting to happen? NPS News. 2004;34:1-4.
76. National Centre for Injury Prevention and Control. Falls and hip fractures among older adults, 2004 (available at www.cdc.gov/ncipc/factsheets/ falls.htm), accessed May 7, 2004.
77. Boonen A, Van Den Heijde D, Landewe R, et al. Large differences in cost-of-illness and well being between patients with fibromyalgia, chronic low back pain or ankylosing spondylitis. Ann Rheum Dis. 2004;63:1264-1268.
78. Walker BF, Muller R, Grant WD. Low back pain in Australian adults. The economic burden. Presented at the Spine Society of Australia Annual Scientific Conference, Canberra, ACT, Australia, 2003.
79. Segal L, Day SE, Chapman AB, et al. Can we reduce disease burden from osteoarthritis? Med J Aust. 2004;180: S11-S17.
80. Moore RA. The hidden costs of arthritis treatment and the cost of new therapy-the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology (Oxford). 2002;41(suppl 1):7-15.
81. Lansberg PG, Pillans PI, Radford JM. Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital. Int J Med. 2003;33:225-228.
82. Amadio P Jr. Peripherally acting analgesics. Am J Med. 1984;77:17-26.
83. Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet. 1982;7:93-107.
84. Bacon TH, Hole JG, North M, et al. Analgesic efficacy of sustained release paracetamol in patients with osteoarthritis of the knee. Br J Clin Pharmacol. 2002;53:629-636.
85. Coulthard P, Hill CM, Frame JW, et al. Pain control with paracetamol from a sustained release formulation and a standard release formulation after third molar surgery: a randomised controlled trial. Br Dent J. 2001;191:319-324.
86. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43:378-385.
87. Pincus T, Swearingen C, Cummins P, et al. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol. 2000;27:1020-1027.
88. Wegman AC, van der Windt DA, de Haan M, Switching from NSAIDs to paracetamol: a series of n of 1 trials for individual patients with osteoarthritis. Ann Rheum Dis. 2003;62:1156-1161.
89. Nikles CJ, Glasziou PP, Del Mar CB, et al. N of 1 trials. Practical tools for medication management. Aust Fam Physician. 2000;29:1108-1112.
90. Sheather-Reid RB, Cohen M. Efficacy of analgesics in chronic pain: a series of N-of-1 studies. J Pain Symptom Manage. 1998;15:244-252.
91. Nikles CJ, Yelland MJ, Glasziou PP, et al. Do individualised medication effectiveness tests (n-of-1 trials) change clinical decisions about which drugs to use for osteoarthritis and chronic pain? Am J Ther. 2005;12:92-97.
92. Australian Bureau of Statistics. 4377.0 National Health Survey, Use of Medications, Australia, 2004 (available at www.abs.gov.au/Ausstats/), accessed July 26, 2004.